This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up
by Zacks Equity Research
BioDelivery Sciences (BDSI) reports in-line loss in Q4. Sales beat the consensus mark. The company issues encouraging guidance for 2019.
Insys Plunges on Auditor's Concern About Insufficient Funds
by Zacks Equity Research
Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.
Allergan Announces FDA Acceptance of Migraine Candidate NDA
by Zacks Equity Research
Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $15.78, marking a +0.19% move from the previous day.
Lilly's Emgality Gets FDA Priority Review for Cluster Headache
by Zacks Equity Research
Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.
Mylan (MYL) Q4 Earnings & Revenues Miss Estimates, Stock Down
by Zacks Equity Research
Mylan (MYL) Q4 earnings and sales miss estimates due to persistent challenges in the North America segment. The guidance for 2019 was weak as well.
Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA
by Zacks Equity Research
The FDA accepts Alkermes (ALKS) and partner Biogen's NDA for diroximel fumarate and sets an action date in the fourth quarter of 2019.
Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Momenta (MNTA) reported a narrower loss in Q4, while sales came ahead of expectations.
Mylan (MYL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when the company reports Q4 results.
Allergan Responds to Investor's Call for CEO/Chair Role Split
by Zacks Equity Research
Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.
Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study
by Zacks Equity Research
Pfizer (PFE) and Eli Lilly (LLY) announce that the higher dose of their investigational pain candidate, tanezumab, significantly reduces chronic low back pain in a late-stage study.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the fourth quarter.
Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down
by Zacks Equity Research
Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.
Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report
by Zacks Equity Research
Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.
Earnings & Data Deluge
by Zacks Equity Research
Earnings & Data Deluge
Markets Keeping Optimistic... For Now; Plus HLT, TEVA, DISH
by Mark Vickery
Pre-market futures are again trading up today, as expectations continue to be favorable for two things that have yet to be officially resolved.
Teva (TEVA) Misses on Q4 Earnings, Beats Sales, Shares Down
by Zacks Equity Research
Teva's (TEVA) fourth-quarter earnings misses estimates but sales beat expectations. Teva???s sales and earnings guidance for 2019 is weaker than expected.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $18.22, marking a -0.71% move from the previous day.
Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down
by Zacks Equity Research
Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued guidance for earnings and sales. Stock drops in pre-market trading.
Why the Earnings Surprise Streak Could Continue for Teva Pharmaceutical Industries Ltd. (TEVA)
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy
by Zacks Equity Research
Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $19.70, moving -0.76% from the previous trading session.
J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study
by Zacks Equity Research
Johnson & Johnson's (JNJ) Erleada improves survival in metastatic castration-sensitive prostate cancer study.
Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study
by Zacks Equity Research
Eli Lilly (LLY) and Pfizer announce that their investigational pain candidate, tanezumab, achieves significant reduction in pain in osteoarthritis patients in second late-stage study.